I suspect they will share the development costs an
Post# of 30029
Although GC has been a huge disappointment to shareholders, a potential partner will only look at what ESS is actually worth. Jason Napadano thought it was worth about 30 million when they first bought it last year. Obviously it's worth a lot more than that if successful in trials.
The biggest naysayers at this point are the same people who thought AMBS was a good investment at $7+, lost all of their money and are angry (and rightfully so) but that doesn't change what the value of ESS is.